Kidney Cancer Drugs Market

Kidney Cancer Drugs Market Outlook 2031

The global kidney cancer drugs market size was USD 6 Billion in 2022 and is projected to reach USD 10.14 Billion by 2031 expand at a substantial CAGR 6% during the forecast period, 2023–2031. The growth of the market is attributed to the availability of novel medications, the presence of a robust pipeline, and the rise in the incidence of kidney cancer as a result of the ageing population and the prevalence of smoking behaviors.

Until the 1980s, kidney cancer was treated by removing the kidneys surgically, followed by laparoscopic excision of the tumor-affected area. Drugs are frequently provided to individuals who are in the advanced stages of the disease condition. At present, various cancer treatment approaches such as vascular endothelial growth factor inhibitor, cytokine therapy, mTOR inhibitor, and immune modulation therapy are commonly adopted for the treatment.

Get Free Sample Report

As per the recent study of the US cancer cases, kidney cancer accounts for nearly 2% of all adult cancers worldwide and 3.8% of all new cancer cases in the country. The study further states that renal cell carcinoma represents for over 90% of all kidney malignancies, while renal pelvis cancer constitutes around 10% of microscopically proven kidney carcinomas.

Several targeted drugs are being introduced and development of new kidney cancer surgery to prevent recurrence present key aspects of the market expansion. Furthermore, in random clinical trials, targeted therapies for kidney cancer demonstrated greater efficacy than standard chemical drug-based chemotherapy. As per the study conducted by Pfizer, targeted therapy is considered to be more effective in terms of preventing tumor spread as compared to using chemical drugs.

Axitinib and Pembrolizumab are the two commercially successful targeted drugs that are widely used for the treatment of stage IV kidney cancer and aid to target the tumor’s spreading areas. Combination therapy is becoming more popular in the market for kidney cancer medications. The therapy combines the effects of multiple medications that lowers the chances of cancer resistant cells forming as it offers a better understanding of the origins and effects of kidney cancer.

Drugs that boost vascular endothelial growth factor (VEGF) in the circulation are paired with inhibitors of mammalian target of Rapamycin (mTor), which helps accelerate cellular biogenesis, in this treatment. According to a study published in 2019 by the National Cancer Institute (NIH), individuals with advanced kidney cancer who receive a mix of treatments have better outcomes.

Merck received the US Food and Drug Administration (FDA) clearance in April 2019 to combine their drug Pembrolizumab, which improves the immune system of patients, with Pfizer's drug Axitinib, to stop the spread of renal cancer. This combination of drugs can help patients recover more quickly in advanced kidney cancer.

Kidney Cancer Drugs Market Trends, Drivers, Restraints, and Opportunities

• Increasing incidence of the type of cancer and rising the global geriatric population who are at risk of developing the disease are expected to boost the market growth during the forecast period.
• Rapid development of new kidney cancer diagnostic tools and innovative therapy methods is projected to fuel the market growth during the forecast period.
• High cost of targeted therapies and strict regulation in drugs approval from regulatory bodies worldwide are anticipated to hamper the market growth.
• Ongoing R&D activities for developing advanced facilities for drug discovery and increasing laboratory testing for several treatment drugs are offering key opportunities for the market expansion.

Scope of The Kidney Cancer Drugs Market Report

The report on the global kidney cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Kidney Cancer Drugs Market Segment Insights

Targeted therapy segment is projected to account for a large market share

Based on therapeutic class, the kidney cancer drugs market is bifurcated into targeted therapy and immunotherapy. The targeted therapy segment is expected to account for a key share of the market during the forecast period as the method is widely used for the kidney cancer treatment when it has spread to other organs and chemical drugs are ineffective.

The growing popularity of innovative immunotherapies and immuno-oncologic drugs is projected to drive the usage of targeted therapies to those patients having critical stage of the disease. This is a major aspect for propelling the segment growth. Combination regimens, particularly those containing PD-1 inhibitors, are offered to be the first-line scenario to address important unmet requirements such as tumor resistance and progression-free survival.

Get Free Sample Report

Asia Pacific is anticipated to dominate the market

On the basis of regions, the kidney cancer drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific is anticipated to dominate the market by expanding at an impressive or healthy CAGR during the forecast period. The regional market growth can be attributed to launching of multiple products pipeline as well as the presence of a large geriatric population susceptible to kidney cancer especially in the region.

Factors such as the continuing Healthy China 2020 healthcare reform as well as the lifting of price limitations on all drug categories are providing major potential for market expansion in China. The Chinese government has put in place measures to boost biotechnology as a critical development industry in the 12th Five-Year Plan. Furthermore, a huge target audience with significant unmet clinical needs is projected to boost the regional market expansion.

Meanwhile, the market of North America is expected to hold a key market share in the coming years owing to wide adoption of innovative methods for drug discovery and extensive research for various treatment drugs from key players based in US in particular. Furthermore, the regional market growth can be attributed to increased therapeutic adoption, established healthcare infrastructure, and the presence of key manufacturers in the region.

Get Free Sample Report

Segments

The global kidney cancer drugs market has been segmented on the basis of

Therapeutic Class

• Targeted Therapy
• Immunotherapy

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Bayer
• Bristol-Myers Squibb
• Eisai
• Exelixis
• Genentech (Roche)
• Novartis
• Pfizer
• Prometheus Labs. 

Competitive Landscape

Key players competing in the global kidney cancer drugs market are Bayer, Bristol-Myers Squibb; Eisai; Exelixis; Genentech (Roche); Novartis; Pfizer; and Prometheus Labs.  These key businesses are concentrating on product development and commercial expansion in emerging markets through clinical alliances. In the field of kidney cancer therapy, biosimilar development is gaining traction as a prospective business opportunity.

Several biotech companies have already released several biosimilars in emerging markets such as India, Russia, and Argentina for a variety of cancer indications.